Abstracts

GUT BARRIER INTEGRITY AND MICROBIOTA IN HIV PATIENTS RECEIVING ORAL BACTERIOTHERAPY

A severe enteropathy with epithelial barrier disruption combined with a chronic T cell immune activation have been reported to characterize HIV-1 immunopathogenesis. Understanding whether the modulation of gut microbiota might promote a reconstitution of intestinal epithelial barrier in HIV-1-infected individuals was the main purpose of the present study. Gut biopsies and fecal samples were collected…

IL-18 AND IL-3 IN EXTRACELLULAR VESICLES: BIOMARKERS FOR A DURABLE ELITE CONTROL

Elite controllers (EC) with a durable control of HIV-1 replication may represent a model of functional cure. Extracellular vesicles (EVs) have emerged as a mechanism for intercellular communication by targeted delivery of cytokines. We evaluated the cytokine profile associated with EVs in well-characterized cohorts of people living with HIV (PLWH) with different virological control status,…

METABOLIC SHIFTS POTENTIATE ACCELERATED AGING IN SUCCESSFUL LONG-TERM HIV TREATMENT

Despite successful antiretroviral therapy (ART), persistent low-grade immune activation together with inflammation and toxic antiretroviral drugs can lead to long-lasting metabolic adaptation in people living with HIV (PLWH). The successful short-term cART reported abnormalities in the metabolic reprogramming in PLWH, but the long-term consequences are unknown. The aim of the present study is to investigate…

HIGH-THROUGHPUT TARGETED PLASMA PROTEOMICS SHOWS SYSTEMIC DYSREGULATION IN PWH ON ART

People with HIV (PWH) in long-term suppressive antiretroviral therapy (ART) are exhibiting increased prevalence of multi-systemic comorbidities compared to the general population. This includes cardiometabolic diseases, HIV-associated neurocognitive disorders, and non-HIV-associated malignancies. Chronic inflammation and microbial dysbiosis are among the major contributors to these major complications in PWH. The main objective of this study is…